Health AI Central
Peer-Reviewed Publication
Am J Manag Care2026;32(9):e334-e342.September 1, 2026Journal Article

Oncology Patients in Clinical Trials: A Health Care Cost Analysis.

Christine Ferro1, Kate Fitch1, Prachi D Bhatt1, Phil Ellenberg1, Bela Bapat2, Adrienne M Gilligan3, Chad Moretz4, Robert H Dumanois5
1Milliman, Inc, New York, NY.
2Illumina, Inc, San Diego, CA.
3Eli Lilly and Company, Indianapolis, IN.
4Invitae, San Francisco, CA.
5Thermo Fisher Scientific, 180 Oyster Point Blvd, San Francisco, CA 94080. Email: robert.dumanois@thermofisher.com.
PubMed DOI

Abstract

OBJECTIVES: To assess health care resource utilization and costs among commercially insured patients with colorectal cancer (CRC) or ovarian cancer (OC) participating in clinical trials (PCTs). STUDY DESIGN: A retrospective claims analysis from 2017 to 2022 was conducted using the Milliman Consolidated Health Cost Guidelines Sources Database, a proprietary database that aggregates deidentified cl…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.